Seven oral traditional Chinese medicine combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis

Kefeng Liu,Qiong Li,Xiaojing Lu,Xintong Fan,Yongjie Yang,Wei Xie,Jian Kang,Shusen Sun,Jie Zhao
DOI: https://doi.org/10.1080/13880209.2024.2351940
2024-05-15
Pharmaceutical Biology
Abstract:Context Traditional Chinese medicines (TCMs) have emerged as potential adjuvant therapies to treat non-small cell lung cancer. More direct comparative studies must be conducted among various oral TCMs.
pharmacology & pharmacy,medical laboratory technology,plant sciences
What problem does this paper attempt to address?
The paper aims to address several key issues in the treatment of non-small cell lung cancer (NSCLC). Specifically: 1. **Efficacy Evaluation**: Evaluate the efficacy of seven oral traditional Chinese medicines (Banmao Capsule, Huachansu Tablet, Hongdoushan Capsule, Kanglaite Capsule, Xihuang Pill, Pingxiao Capsule, and Zilongjin Tablet) in combination with chemotherapy through network meta-analysis. 2. **Disease Control Rate (DCR)**: The study found that Banmao Capsule and Huachansu Tablet performed best in improving the disease control rate. 3. **Objective Response Rate (ORR)**: Banmao Capsule and Zilongjin Tablet showed significant effects in improving the objective response rate. 4. **Karnofsky Performance Status (KPS) Improvement**: Zilongjin Tablet and Huachansu Tablet performed best in improving patients' quality of life. 5. **Side Effects Reduction**: The effects of different Chinese medicines in reducing gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, thrombocytopenia, and leukopenia were also evaluated. In summary, the main objective of this paper is to systematically compare the efficacy and safety of these oral Chinese medicines in combination with chemotherapy, providing clinicians with a basis for selecting more effective treatment options.